Hypoxia‐inducible factor 1A inhibition overcomes castration resistance of prostate tumors
EMBO Molecular Medicine · 2023
DOI: 10.15252/emmm.202217209 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMBO Molecular Medicine, 2023. Verfasst von Julie Terzic und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, Centre National de la Recherche Scientifique, Fondation ARC pour la Recherche sur le Cancer.
Abstract (Originalsprache)
Androgen deprivation therapy (ADT) is a cornerstone of prostate cancer (PCa) management. Although tumors initially regress, many progress to a hormone‐independent state termed castration‐resistant PCa (CRPC), for which treatment options are limited. We here report that the major luminal cell population in tumors of Pten (i)pe−/− mice, generated by luminal epithelial cell‐specific deletion of the tumor suppressor PTEN after puberty, is castration‐resistant and that the expression of inflammation and stemness markers is enhanced in persistent luminal cells. In addition, hypoxia‐inducible factor 1 (HIF1) signaling, which we have previously demonstrated to be induced in luminal cells of Pten (i)pe−/− mice and to promote malignant progression, is further activated. Importantly, we show that genetic and pharmacological inhibition of HIF1A sensitizes Pten‐deficient prostatic tumors to castration and provides durable therapeutic responses. Furthermore, HIF1A inhibition induces apoptotic signaling in human CRPC cell lines. Therefore, our data demonstrate that HIF1A in prostatic tumor cells is a critical factor that enables their survival after ADT, and identify it as a target for CRPC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.
- Centre National de la Recherche Scientifique (CNRS), UMR7104, Illkirch, France.
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1258, Illkirch, France.
- Université de Strasbourg, Strasbourg, France.
- Institute for Diabetes and Cancer, Helmholtz Center Munich, and German Center for Diabetes Research (DZD), Neuherberg, Germany.
ORCID-Profile: Julie Terzic, Mohamed A Abu El Maaty, Régis Lutzing, Céline Keime, Daniel Metzger
Förderung
- Agence Nationale de la Recherche
- Centre National de la Recherche Scientifique
- Fondation ARC pour la Recherche sur le Cancer
- Fondation pour la Recherche Médicale
- Institut National de la Santé et de la Recherche Médicale
- Institut National Du Cancer
- ITMO Cancer/INCa
- Université de Strasbourg
Zitieren
APA
Terzic, J., Abu El Maaty, M. A., Lutzing, R., Vincent, A., El Bizri, R., Jung, M., Keime, C., & Metzger, D. (2023). Hypoxia‐inducible factor 1A inhibition overcomes castration resistance of prostate tumors. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202217209
Vancouver
Terzic J, Abu El Maaty MA, Lutzing R, Vincent A, El Bizri R, Jung M, et al. Hypoxia‐inducible factor 1A inhibition overcomes castration resistance of prostate tumors. EMBO Molecular Medicine. 2023. doi:10.15252/emmm.202217209
BibTeX
@article{Terzic2023,
author = {Terzic, Julie and Abu El Maaty, Mohamed A and Lutzing, Régis and Vincent, Alexandre and El Bizri, Rana and Jung, Matthieu and Keime, Céline and Metzger, Daniel},
title = {Hypoxia‐inducible factor 1A inhibition overcomes castration resistance of prostate tumors},
journal = {EMBO Molecular Medicine},
year = {2023},
doi = {10.15252/emmm.202217209}
}
EUVIMED